First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.

Basit Öğe Kaydı
dc.authorid0000-0001-5350-7241
dc.authorid0000-0003-4478-7282
dc.contributor.authorLoriot, Yohann
dc.contributor.authorGrivas, Petros
dc.contributor.authorDe Wit, Ronald
dc.contributor.authorBalar, Arjun Vasant
dc.contributor.authorSiefker-Radtke, Arlene O.
dc.contributor.authorZolnierek, Jakub
dc.contributor.authorCsoszi, Tibor
dc.date.accessioned2025-05-10T19:34:30Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionASCO Genitourinary Cancers Symposium -- FEB 17-19, 2022 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Soc Clin Oncol
dc.description.sponsorshipMerck Sharp Dohme Corp.; Eisai Inc., Woodcliff Lake, NJ, USA
dc.description.sponsorshipMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and Eisai Inc., Woodcliff Lake, NJ, USA.
dc.identifier.doi10.1200/JCO.2022.40.6_suppl.432
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue6
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1200/JCO.2022.40.6_suppl.432
dc.identifier.urihttps://hdl.handle.net/20.500.14730/8548
dc.identifier.volume40
dc.identifier.wosWOS:000771008900438
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleFirst-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu